8-K: Veracyte Q3 2025 Revenue Jumps 14%, Raises Full-Year Guidance

Veracyte, Inc. announced strong third-quarter 2025 financial results, with total revenue increasing 14% and testing revenue up 17% year-over-year, leading to an upward revision of its full-year revenue and profitability guidance.

Summary

• Total revenue increased 14% year-over-year to $131.9 million for the third quarter ended September 30, 2025.
• Testing revenue grew 17% year-over-year to $127.8 million.
• Total volume increased 18% to 45,888 tests, and testing volume rose 19% to 43,679 tests.
• Decipher revenue grew 26% to $82.2 million, and Afirma revenue increased 7% to $43.2 million.
• GAAP net income was $19.1 million, or 15% of revenue, which included a $6.7 million loss related to the deconsolidation of the Veracyte SAS entity.
• Adjusted EBITDA reached $39.7 million, representing 30% of revenue.
• Generated $44.8 million of cash from operations, ending the quarter with $366.4 million in cash, cash equivalents, and short-term investments.
• Full-year 2025 total revenue guidance was raised to $506 million to $510 million, up from prior guidance of $496 million to $504 million.
• Full-year 2025 testing revenue guidance was raised to $484 million to $487 million, implying 16% year-over-year growth, up from prior guidance of $477 million to $483 million.
• Full-year 2025 adjusted EBITDA as a percentage of revenue guidance was raised to over 25%, up from the prior guidance of 23.5%.

Sentiment

Score: 8

Explanation: The company reported strong financial results with significant revenue and EBITDA growth, and raised its full-year guidance, indicating positive momentum and confidence in future performance. The only minor negative was the loss related to the deconsolidation of Veracyte SAS, which was already factored into GAAP net income.

Positives

• Total revenue increased by a strong 14% to $131.9 million compared to the same period in 2024.
• Testing revenue showed robust growth of 17% to $127.8 million year-over-year.
• Total test volume increased by 18% to 45,888 tests, indicating strong demand for products.
• Decipher revenue surged by 26% to $82.2 million, and Afirma revenue grew by 7% to $43.2 million.
• GAAP net income improved by 26% to $19.1 million compared to the third quarter of 2024.
• Adjusted EBITDA significantly improved by 45% to $39.7 million, expanding the adjusted EBITDA margin to 30.1% from 23.6% in the prior year.
• Generated substantial cash from operations of $44.8 million in the quarter, contributing to a healthy cash balance of $366.4 million.
• Raised full-year 2025 revenue and profitability guidance, reflecting increased confidence in future performance.
• Presented nine Decipher-focused abstracts at ASTRO 2025, including validation data from the BALANCE trial demonstrating PAM50 molecular signature predicts hormone therapy benefit.
• Published data in Cell from the STAMPEDE trial showing the Decipher Prostate Genomic Classifier predicts chemotherapy benefit in metastatic prostate cancer patients.
• Launched the Afirma v2 transcriptome to enhance efficiency and serve as a platform for future product launches.
• Completed NIGHTINGALE clinical utility trial enrollment for the Percepta Nasal Swab test.

Negatives

• Biopharmaceutical and other revenue decreased to $0.8 million from $3.1 million in the prior year, attributed to the restructuring and liquidation proceedings of Veracyte SAS.
• GAAP net income for the quarter included a $6.7 million loss related to the deconsolidation of the Veracyte SAS entity.

Risks

• Ability to launch, commercialize, and receive reimbursement for products.
• Ability to execute on business strategies relating to the C2i Genomics acquisition, integration of the business, and realization of expected benefits and synergies.
• Ability to demonstrate the validity and utility of genomic tests and biopharma and other offerings.
• Ability to continue executing on the business plan.
• Ability to continue to scale global operations and enhance the internal control environment.
• Impact of the war in Ukraine and other regional conflicts on European economies.
• Impact of foreign currency fluctuations, volatile interest rates, and inflation.
• Impact of legislation and policies enacted by the current U.S. administration.
• Turmoil in the global banking and finance system.
• Ongoing conflict in the Middle East.
• Performance and utility of tests in the clinical environment.

Future Outlook

Veracyte has raised its full-year 2025 total revenue guidance to $506 million to $510 million, and testing revenue guidance to $484 million to $487 million, representing 16% year-over-year growth. The company also increased its adjusted EBITDA as a percentage of revenue guidance to over 25% for the full year, reflecting confidence in durable, long-term growth from its broad portfolio and upcoming product launches like TrueMRD and Prosigna LDT.

Management Comments

• "We delivered another outstanding quarter of testing revenue growth and adjusted EBITDA margin expansion, enabling us to raise both our revenue and profitability guidance."
• "We continue to advance our mission of transforming cancer care by generating high-quality evidence and clinical insights that reinforce the value of our tests and our market leadership."
• "The strong momentum we have seen this year, combined with our upcoming TrueMRD and Prosigna LDT launches, gives us confidence in delivering durable, long-term growth from our broad portfolio of tests covering the care continuum in multiple indications."

Industry Context

Veracyte operates in the competitive and rapidly evolving cancer diagnostics industry, leveraging genomic and clinical data, bioinformatics, and AI. The strong growth in testing revenue, particularly from its Decipher and Afirma platforms, indicates robust demand for its high-value diagnostic tests. The company's focus on generating high-quality evidence and securing guideline inclusion positions it as a leader, while upcoming product launches like TrueMRD and Prosigna LDT suggest continued innovation and expansion across the cancer care continuum.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other companies, projects, or global benchmarks within the industry.

Legal Proceedings

• Non-GAAP adjustments for Q3 2025 included expenses related to 'other legal proceedings' ($0.5 million).
• Non-GAAP adjustments for Q3 2025 included an offset from a 'vendor legal settlement' ($2.8 million).

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased profitability, raised guidance, and potential for durable long-term growth.
• Patients: Benefit from continued advancement of cancer care through high-quality diagnostic tests and clinical insights.
• Clinicians: Empowered with high-value insights to guide patient care.
• Employees: Continued growth and innovation may lead to stable or expanding opportunities.

Next Steps

• Launch of TrueMRD.
• Launch of Prosigna LDT.
• Host a conference call and webcast on November 4, 2025, at 4:30 p.m. ET to discuss financial results and provide a general business update.

Key Dates

Recommendation

The company delivered robust Q3 2025 financial results, significantly exceeding prior year performance in key metrics like total revenue, testing revenue, and adjusted EBITDA. The upward revision of full-year guidance for both revenue and profitability demonstrates strong operational execution and positive future outlook. The continued growth of core products like Decipher and Afirma, coupled with upcoming product launches, indicates sustained market leadership and potential for durable long-term growth in the high-demand cancer diagnostics sector. The strong cash generation further strengthens the company's financial position.

Keywords

cancer diagnostics, genomic tests, Veracyte, VCYT, Decipher Prostate, Afirma, thyroid cancer, prostate cancer, lung cancer, biopharmaceutical, EBITDA, revenue growth, financial results, Q3 2025, guidance